COVID-19 is an acute respiratory distress syndrome and is often accompanied by gastrointestinal symptoms. The SARS-CoV-2 has been traced not only in nasopharyngeal and mid-nasal swabs but also in stool and rectal swabs of COVID-19 patients. The gut microbiota is important for an effective immune response as it ensures that unfavorable immune reactions in lungs and other vital organs are regulated. The human gut-lung microbiota interplay provides a framework for therapies in the treatment and management of several pulmonary diseases and infections. Here, we have collated data from COVID-19 studies, which suggest that bacterial co-infections as well as the gut-lung cross talk may be important players in COVID-19 disease prognosis. Our analyses suggests a role of gut microbiome in pathogen infections as well as in an array of excessive immune reactions during and post COVID-19 infection recovery period.
【저자키워드】 SARS-CoV-2, Probiotics, gut-lung axis, angiotensin-converting enzyme 2, Opportunistic Pathogens, Gut-microbiome, 【초록키워드】 COVID-19, Treatment, immune response, therapy, Prognosis, Infection, lung, COVID-19 disease, Stool, infections, microbiota, pathogen, COVID-19 infection, nasopharyngeal, management, Microbiome, gut microbiota, Swab, bacterial co-infection, COVID-19 patients, pulmonary disease, acute respiratory distress, gastrointestinal symptoms, Analysis, Gut, syndrome, organ, immune reaction, rectal swab, effective, provide, regulated, accompanied, cross talk, 【제목키워드】 COVID-19, severity, Bacterial, Gut, implication,